Healthcare - Biotechnology - NASDAQ - US
$ 1.38
-13.2 %
$ 190 M
Market Cap
-3.94
P/E
CASH FLOW STATEMENT
-40.6 M
OPERATING CASH FLOW
27 M
INVESTING CASH FLOW
2.94 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Compass Therapeutics, Inc.
| Net Income | -42.5 M |
| Depreciation & Amortization | 1.89 M |
| Capital Expenditures | -30 K |
| Stock-Based Compensation | 6.12 M |
| Change in Working Capital | -2.91 M |
| Others | 2.35 M |
| Free Cash Flow | -40.6 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Mar-2020 | Mar-2019 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (42.5) | (39.2) | (82.2) | (29.5) | (34.7) | (38.3) |
| Depreciation & Amortization | 1.9 | 1.9 | 1.6 | 2.4 | 2.1 | 1.9 |
| Deferred Income Tax | 0 | 0 | 50.6 | 0.8 | 0.1 | (0.3) |
| Stock Based Compensation | 6.1 | 5.3 | 4.0 | 4.0 | 0.9 | 0.7 |
| Other Operating Activities | 6.0 | (0.9) | 41 K | (1.0) | 0.1 | 0.1 |
| Change in Working Capital | (2.9) | (1.3) | 6.2 | (3.6) | (0.3) | 2.2 |
| Cash From Operations | (40.6) | (34.1) | (19.7) | (26.8) | (31.7) | (33.7) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | 30 K | (0.2) | (1.6) | (0.1) | (0.5) | (2.0) |
| Other Items | 27.0 | (151.0) | (0.2) | 0.1 | 0 | 0 |
| Cash From Investing Activities | 27.0 | (151.2) | (1.8) | 38 K | (0.5) | (2.0) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 159 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (0.2) | (0.5) | (0.3) | (6.3) | 37.6 K | 64.0 |
| Cash From Financing Activities | 2.9 | 75.8 | 118.6 | 48.5 | 37.6 K | 64.0 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (10.7) | (109.6) | 97.2 | 21.8 | (32.2) | 28.3 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (40.6) | (34.3) | (21.2) | (26.9) | (32.2) | (35.7) |